207 related articles for article (PubMed ID: 35682800)
1. EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.
Zhang C; Sheng W; Al-Rawe M; Mohiuddin TM; Niebert M; Zeppernick F; Meihold-Heerlein I; Hussain AF
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682800
[TBL] [Abstract][Full Text] [Related]
2. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
Mungra N; Biteghe FAN; Malindi Z; Huysamen AM; Karaan M; Hardcastle NS; Bunjun R; Chetty S; Naran K; Lang D; Richter W; Hunter R; Barth S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12203-12225. PubMed ID: 37432459
[TBL] [Abstract][Full Text] [Related]
3. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
[TBL] [Abstract][Full Text] [Related]
4. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
5. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.
Amoury M; Bauerschlag D; Zeppernick F; von Felbert V; Berges N; Di Fiore S; Mintert I; Bleilevens A; Maass N; Bräutigam K; Meinhold-Heerlein I; Stickeler E; Barth S; Fischer R; Hussain AF
Oncotarget; 2016 Aug; 7(34):54925-54936. PubMed ID: 27448975
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells.
Woitok M; Klose D; Di Fiore S; Richter W; Stein C; Gresch G; Grieger E; Barth S; Fischer R; Kolberg K; Niesen J
Onco Targets Ther; 2017; 10():3313-3327. PubMed ID: 28740407
[TBL] [Abstract][Full Text] [Related]
7. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
8. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
[TBL] [Abstract][Full Text] [Related]
9. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
Khandelwal S; Boylan M; Spallholz JE; Gollahon L
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
13. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
[TBL] [Abstract][Full Text] [Related]
14. A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo.
Guo P; Huang J; Zhu B; Huang AC; Jiang L; Fang J; Moses MA
Sci Adv; 2023 May; 9(18):eabq7866. PubMed ID: 37146146
[TBL] [Abstract][Full Text] [Related]
15. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
18. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
Suthe SR; Yao HP; Weng TH; Wang MH
Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965
[TBL] [Abstract][Full Text] [Related]
19. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
